Abhijit Narvekar

Learn More
We examined the neural response patterns for facial identity independent of viewpoint and for viewpoint independent of identity. Neural activation patterns for identity and viewpoint were collected in an fMRI experiment. Faces appeared in identity-constant blocks, with variable viewpoint, and in viewpoint-constant blocks, with variable identity.(More)
BACKGROUND Symptom relief for the duration of 24 hours after treatment would benefit patients with allergic conjunctivitis. OBJECTIVE To compare the safety and efficacy of olopatadine 0.77% with vehicle or olopatadine 0.2% in patients with allergic conjunctivitis in a conjunctival allergen-challenge clinical study. PATIENTS AND METHODS In this Phase(More)
Psychological research indicates that humans recognize faces of their own race more accurately than faces of other races. This “other-race effect” occurs for algorithms tested in a recent international competition for state-of-the-art face recognition algorithms. We report results for a Western algorithm made by fusing eight algorithms from(More)
We present a synopsis of results comparing the performance of humans with face recognition algorithms tested in the Face Recognition Vendor Test (FRVT) 2006 and Face Recognition Grand Challenge (FRGC). Algorithms and humans matched face identity in images taken under controlled and uncontrolled illumination. The human-machine comparisons include accuracy(More)
PURPOSE To assess the efficacy and safety of a novel once-daily 0.77% olopatadine hydrochloride ophthalmic solution in subjects with allergic conjunctivitis (AC) using the conjunctival allergen challenge (CAC) model. METHODS In this 5-week, multicenter, double-masked, phase 3, randomized trial, subjects aged ≥18 years with a history of AC and a confirmed(More)
PURPOSE To assess the pharmacokinetics and safety of hydrochloride ophthalmic solution 0.77% olopatadine from 2 independent (Phase I and Phase III, respectively) clinical studies in healthy subjects. MATERIALS AND METHODS The Phase I, multicenter, randomized (2:1), vehicle-controlled study was conducted in subjects ≥18 years old (N=36) to assess the(More)
PURPOSE Two individual phase 3 conjunctival allergen challenge (CAC) studies of similar design have assessed the efficacy and safety of olopatadine hydrochloride (HCl) 0.77% for the treatment of allergic conjunctivitis. The purpose of this study is to evaluate the integrated efficacy and safety of olopatadine HCl 0.77% from a larger dataset by pooling data(More)
  • 1